Article
Pfizer jumps into bed with Agomab, leading series B extension and lending support to Crohn's program
Rating:
0.0
Views:
39
Likes:
1
Library:
1
Pfizer led the $40.5 million extension to a series B round and agreed to provide expertise in support of a Crohn's disease candidate.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value